APOA5 Human
Description
APOA5 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
Apolipoprotein A-V was first identified in 2001 through comparative genomics. It is encoded by the APOA5 gene, located on chromosome 11q23. The protein consists of 366 amino acids and has a molecular weight of approximately 40 kDa. The recombinant form of ApoA-V is often produced in HEK 293 cells, ensuring high purity and functionality .
ApoA-V is a potent regulator of serum triglyceride concentrations. It exerts its effects through several mechanisms:
- Enhancing Lipoprotein Lipase (LPL) Activity: ApoA-V promotes the hydrolysis of triglycerides in very low-density lipoproteins (VLDL) by activating LPL, an enzyme critical for triglyceride breakdown.
- Inhibiting Hepatic VLDL Secretion: ApoA-V reduces the secretion of VLDL particles from the liver, thereby lowering the amount of triglycerides released into the bloodstream.
- Facilitating Receptor-Mediated Uptake: ApoA-V enhances the clearance of triglyceride-rich lipoproteins by promoting their uptake via hepatic receptors.
Mutations or variations in the APOA5 gene are associated with hypertriglyceridemia, a condition characterized by elevated levels of triglycerides in the blood. This condition is a risk factor for cardiovascular diseases, including coronary artery disease and pancreatitis. Understanding the role of ApoA-V in lipid metabolism has significant implications for developing therapeutic strategies to manage hypertriglyceridemia and related disorders.
Recombinant human ApoA-V is produced using advanced biotechnological methods. The protein is expressed in HEK 293 cells, which are human embryonic kidney cells commonly used for protein production due to their high transfection efficiency and ability to perform post-translational modifications. The recombinant protein is purified to a high degree, with a purity of over 70% as determined by SDS-PAGE .
Recombinant ApoA-V is used in various research applications, including:
- Studying Lipid Metabolism: Researchers use recombinant ApoA-V to investigate its role in lipid metabolism and its potential as a therapeutic target for hypertriglyceridemia.
- Drug Development: The protein is used in the development of drugs aimed at regulating triglyceride levels and preventing cardiovascular diseases.
- Biochemical Assays: Recombinant ApoA-V is employed in assays to study its interaction with other proteins and lipids, providing insights into its mechanism of action.
